During this year´s AACR Annual Meeting, Washington DC, April 6 -10, ecancer caught up with VHIO´s Laura Soucek, PI of the Mouse Models of Cancer Therapies Group, to discuss her group´s pioneering work on Myc inihibition in pre-clinical mouse models.
Related Posts
Novel drug reduces risk of metastatic prostate cancer progression by 81%
Presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 03, Chicago IL, USA, the Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) have participated in an international phase III study published in the New England Journal of Medicine. Findings show that the administration of the drug enzalutamide prior to chemotherapy in metastatic prostate cancer patients reduces disease progression of by 81% — consequently postponing initiation of treatment with the latter, and leading to increased survival and improved quality of life for patients.
02 Jun 2014
VHIO´s Javier Cortes comments: Two Anti-HER2 Antibodies Better than One
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
Co-author Javier Cortés, Principle Investigator of VHIO´s Breast Cancer and Melanoma Group, describes the CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) randomized trial, the importance and implications of the findings, as well as signposts future directions.
29 Dec 2011
Final chance to sumbit your abstract for VHIO´s Special Symposium: Towards Predictive Cancer Models
Abstract submission deadline, close of business Monday 18 April, is rapidly approaching. The next couple of days represent the final…
15 Apr 2016
Sponsored Walking to Support Research Aimed at Improved Treatment & Care in Breast Cancer: El Paseíco de la Mama
Inés Gasén was diagnosed with breast cancer during her pregnancy – not only naturally provoking fear and uncertainty for her…
25 May 2013
New Investigational Drug Targeting Difficult to Treat Breast Cancers to Undergo Pan-European Phase II Clinical Trials
Cancer researchers, oncologists and international pharmaceutical company join forces to test a new investigational drug for breast cancer Barcelona, 05…
05 Oct 2015
Announced today by GSK: VHIO joins five other international research centers of excellence as member of the Oncology Clinical and Translational Consortium (OCTC)
• GSK undertakes global consortium incorporating six prestigious cancer research centers • The Oncology Clinical and Translational Consortium (OCTC) includes…
05 Dec 2013
VHIO´s Enriqueta Felip: recipient of the recently launched ESMO Women for Oncology Award
Source: The European Society for Medical Oncology (ESMO) Lugano, Switzerland, 27 August 2015 — The European Society for Medical Oncology…
01 Sep 2015
Backing breast cancer research of excellence: the Conquer Cancer Foundation awards VHIO´s Cristina Cruz
Celebrated last week during the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), Cristina Cruz receives a…
04 Jun 2015
EurocanPlatform: combining forces in the fight against the world´s deadliest disease
VHIO and 27 other leading European Cancer Institutes are working together in a unique collaboration to share infrastructures and collaborate on projects to help advance cancer research and treatment: EurocanPlatform
20 Sep 2011
The passing of one of the greatest supporters of biomedical research and healthcare across Catalonia: Dr. Pere Mir
It is with deep regret and sadness that we write to report the passing of one of the greatest supporters…
13 Mar 2017
A hand-pick of VHIO highlights on the ground at the Annual Meeting of the American Association for Cancer Research (AACR), 01 – 05 April, Washington, DC
Showcased during AACR´s 2017 Annual Meeting´s Opening Plenary: The Road to Cancer Cures – Discover, Predict, Prevent and Treat, Sunday…
28 Apr 2017
Sponsored walking to support liquid biopsy-based breast cancer research: El Paseíco de la Mama
Last week ´s seventh El Paseíco de la Mama 7.5 Km sponsored walk along Zaragoza´s canal will raise essential funding…
31 May 2017
Exploring mechanisms of resistance against ER+ and BRCA1 breast cancer therapies
• Various research lines led by VHIO aim at better deciphering how tumor cells acquire resistance to anticancer agents including…
08 Sep 2016
VHIO scientists and AICR Atlas trekking team to raise funds for cancer research: donate today
Comprised of AICR (now rebranded as Worldwide Cancer Research) donors, supporters, staff and AICR grant holders, some 15 individuals, including VHIO´s…
03 Mar 2014
DUE TO POPULAR DEMAND ADDITIONAL GIG ON 20 DECEMBER – Jarabe de Palo´s Pau Donés: singing to support crucial research into novel therapies against colorectal cancer
IMPORTANT NOTIFICATION: As an update to this earlier news item (see below), Pau´s fundraising concert on the 22nd December is…
23 Nov 2015
